COLON CANCER GENETICS - surgerysymposium.org
Transcript of COLON CANCER GENETICS - surgerysymposium.org
![Page 1: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/1.jpg)
COLON CANCER GENETICS (FOR SURGEONS)
Mark W. Arnold MDChief, Division of Colon and Rectal SurgeryProfessor of SurgeryThe Ohio State University
![Page 2: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/2.jpg)
DISCLAIMERS
1. I am a surgeon; of course I have nothing to disclose.
2. I am not a geneticist; which will be obvious after listening to this presentation.
![Page 3: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/3.jpg)
KEY POINTS OF DISCUSSION
Knudson’s two hit hypothesis.
Probability of developing colon cancer.
Less common genetic syndromes.
FAP.
Lynch syndrome.
Pedigrees.
![Page 4: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/4.jpg)
KNUTSON’S TWO HIT HYPOTHESIS
Multiple “hits” in the DNA are required to cause cancer. The first hit is inherited, the second hit acquired.
![Page 5: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/5.jpg)
MOLECULAR PATHWAYS LEADING TO COLON AND RECTAL CARCINOGENESIS
Chromosomal instability (CIN), which accounts for approximately 85% of colorectal cancers.
Microsatellite instability (MSI), or replication error, which accounts for approximately 15% of colorectal cancers.
![Page 6: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/6.jpg)
Adapted from Burt RW et al. Prevention and Early Detection of CRC, 1996
Sporadic (65%–85%)
Familial (10%–30%)
Hereditary nonpolyposis colorectal cancer (HNPCC) (5%)Familial adenomatous
polyposis (FAP) (1%)
Rare CRC syndromes
(<0.1%)
ASCO
SUSCEPTIBILITY to CRC
![Page 7: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/7.jpg)
RISK OF COLORECTAL CANCER (CRC)
0 20 40 60 80 100
General population
Personal history of colorectal neoplasia
Inflammatory bowel disease
HNPCC mutation
FAP
5%
15%–20%
15%–40%
70%–80%
>95%
Lifetime risk (%)ASCO
![Page 8: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/8.jpg)
RELATIVE AND ABSOLUTE RISK OF CRC
Family History Relative Risk Absolute Risk, age 79
No family history 1 4%
1 first degree relative with adenoma
2.0 8%
1 first degree relative w CRC
2.3 9%
1 first degree relative with CRC before age 45
3.9 15%
> 1 first degree relative w CRC
4.3 16%
![Page 9: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/9.jpg)
RARE GENETIC SYNDROMES
![Page 10: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/10.jpg)
PEUTZ-JEGHERS SYNDROME
STK11 gene, chromosome 19
GI hamartomas
Characteristic pigmentation
2%–13% lifetime CRC risk
Other cancers include small bowel, pancreas, ovary and other sex-cord tumors
![Page 11: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/11.jpg)
JUVENILE POLYPOSIS COLI
Autosomal dominant (rare)
Linked to PTEN in some families; 18q in others
Juvenile polyps with mixed adenomatous histology
Olschwang S et al. Nature Genetics 18:12, 1998 ASCO
![Page 12: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/12.jpg)
MYH POLYPOSIS (MAP)
Caused by mutations in the MyH gene on the short arm of Chromosome 1.
MUTYH glycosylase is involved in oxidative DNA damage repair.
There are two common mutations are Y165C and G382D.
Autosomal recessive.
Risk of cancer at age 20 – 50.
Screening colonoscopy starting age 18.
Increased risk for stomach cancer.
![Page 13: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/13.jpg)
FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
![Page 14: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/14.jpg)
CLINICAL FEATURES OF FAP
Estimated penetrance for adenomas >90%
Risk of extracolonic tumors (upper GI, desmoid, osteoma, thyroid, brain, other)
Ophthalmolic lesions may be present (CHRPE)
Untreated polyposis leads to 100% risk of cancer
ASCO
![Page 15: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/15.jpg)
GENETICS OF FAP
Autosomal dominant inheritance
Caused by mutations in APC tumor suppressor gene on chromosome 5q
Up to 30% of patients have de novo germline mutations
Most families have unique mutations
Most mutations are protein truncating
![Page 16: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/16.jpg)
FAP FAMILY WITH APC MUTATION
Mutation carrier
FAP
FAP and CRC
CRC d. 45
FAP 25, CRC d. 31 Age 59FAP, 22
colectomy
Age 42 FAP 38, APC+
Age 40APC–
Negative sigmoidoscopies
(age 33)
Age 16APC+
Age 14APC–
Age 52
![Page 17: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/17.jpg)
DE NOVO GERMLINE MUTATIONS IN FAP
De novo germline mutations occur in ~30% of FAP cases
FAPCRC, 45
de novo
mutation
![Page 18: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/18.jpg)
0
20
40
60
80
100
FAP: AGE AND DEVELOPMENT OF ADENOMAS AND CRC
Patients with
neoplasia
Age20 40 60 80
FAP
General population
AdenomasCRC
ASCO
![Page 19: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/19.jpg)
ATTENUATED FAP
Later onset (CRC ~age 50)
Few colonic adenomas No retinal lesions UGI lesions Associated with
mutations at 5' and 3'ends of APC gene
ASCO
![Page 20: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/20.jpg)
INDICATIONS FOR APC GENE TESTING
Molecular diagnosis of FAP in patients who present with:
polyposis (>100 adenomas)
attenuated FAP
Predictive testing for FAP in blood relatives of persons with FAP or known APC mutations
Giardiello FM et al. N Engl J Med, 336:823, 1997
![Page 21: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/21.jpg)
GENETIC SUSCEPTIBILITY TESTING FOR FAP
Limitations False-negative results
may lead to underestimated CRC risk
APC mutation tests are not informative in all FAP families
Benefits Identifies non-mutation
carriers, who require only population screening for CRC
Identifies APCmutation carriers, in whom early disease intervention may be lifesaving
![Page 22: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/22.jpg)
EARLY MANAGEMENT OF FAP
Endoscopy beginning at age 10
Removal of polyps
Abdominal U/S for hepatoblastoma (birth to 5 yrs)
Dilated eye exam (ophthalmologist)
Upper EGD: when colon polyps develop or age 25
![Page 23: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/23.jpg)
MANAGEMENT OF FAP
Annual thyroid exam If symptoms develop:
Panorex of jaw and/or skull X-ray Abdominal and pelvic CT
Total colectomy is usually necessary when polyps become too numerous to remove with standard techniques often by age 25.
![Page 24: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/24.jpg)
SURGICAL OPTIONS
Total colectomy with ileo-rectal anastomsis.
Total proctocolectomy with end ileostomy.
Total proctocolectomy with ileo-anal pouch reconstruction.
![Page 25: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/25.jpg)
TECHNICAL CONSIDERATIONSILEO-ANAL RECONSTRUCTION
S-pouch vs. J-pouchMucosectomy vs. double stapleTemporary ileostomy vs. no ileostomy
![Page 26: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/26.jpg)
AN OPERATION IN 5 STEPS
Step 1: ColectomyStep 2: ProctectomyStep 3: Ileal Pouch Step 4: AnastomosisStep 5: Loop Ileostomy
![Page 27: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/27.jpg)
COLECTOMY: ILEAL DIVISION
![Page 28: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/28.jpg)
COLECTOMY: SIGMOID DIVISION
![Page 29: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/29.jpg)
PROCTECTOMY: POSTERIOR DISSECTION
![Page 30: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/30.jpg)
PROCTECTOMY: DISTAL DIVISION
![Page 31: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/31.jpg)
ILEAL POUCH: PLICATION
![Page 32: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/32.jpg)
ILEAL POUCH: COMMON WALL DIVISION
![Page 33: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/33.jpg)
ILEAL POUCH: PLACING THE PURSTRING
![Page 34: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/34.jpg)
ILEAL POUCH: PLACING THE ANVIL
![Page 35: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/35.jpg)
ANASTOMOSIS: DISTAL INSERTION
![Page 36: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/36.jpg)
ANASTOMOSIS: ILEOPROCTOSTOMY
![Page 37: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/37.jpg)
ILEOSTOMY: TEMPORARY STOMA PLACEMENT
![Page 38: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/38.jpg)
ILEOSTOMY: MATURING THE STOMA
![Page 39: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/39.jpg)
FAP Pedigree - MC
Ileo-rectal: Rectal cancerCrohn’s DiseaseDuodenal cancer.
Total proctocolectomy and ileostomy
J pouchS pouch
![Page 40: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/40.jpg)
FAP Pedigree - MM
J pouch age 14;Rectal cancer age 28
Rectal Cancer age 36
Untreated age 14
Ileorectal age 18
J pouch age 25;Disease free
![Page 41: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/41.jpg)
FAP IMPORTANT POINTS
Wide range of expression.
May be de novo mutation.
Early diagnosis and treatment.
Surgical approach should be tailored to the patient.
Lifetime close follow-up is needed.
High risk of developing malignancy.
![Page 42: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/42.jpg)
HEREDITARY NONPOLYPOSISCOLORECTAL CANCER
![Page 43: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/43.jpg)
Clinical Features of HNPCC• Early but variable age at CRC
diagnosis (~45 years)• Tumor site in proximal colon
predominates• Extra-colonic cancers:
endometrium, ovary, stomach, urinary tract, small bowel, bile ducts, sebaceous skin tumors
![Page 44: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/44.jpg)
Cancer Risks in HNPCC
Aarnio M et al. Int J Cancer 81:217, 1999
% with cancer
100
80
60
40
20
020 40 60 800
Age (years)
Colorectal 82%
Endometrial 60%
Stomach 13%Ovarian 12%Urinary tract 4%Brain 3.7%
ASCO
![Page 45: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/45.jpg)
Amsterdam Criteria II 3 or more relatives with verified HNPCC-
associated cancers* in family One case a first-degree relative of the other two Two or more generations One CRC by age 50 FAP excluded
Vasen HFA et al. Gastroenterology 116:1453, 1999
*HNPCC associated cancers: CRC, endometrial, small bowel, ureter, renal pelvis
![Page 46: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/46.jpg)
BETHESDA GUIDELINES- REVISED 2004
To identify patients for MSI testing Amsterdam criteria or Individual with CRC dx <50 yo Synchronous or metachronous CRC, or other HNPCC-
associated tumors regardless of age CRC with MSI-H histology dx <60 yo CRC with >1 FDR with an HNPCC-associated tumor, with
one cancer dx <50 CRC with >2 FDRs or SDRs with an HNPCC-associated
tumor, regardless of age
Umar A, et al. JNCI. 2004;96(4):261-268.
International Workshop HNPCC Dec 2002, Bethesda, MD
![Page 47: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/47.jpg)
GENETIC FEATURES OF HNPCC
Autosomal dominant inheritance Penetrance ~80% Genes belong to DNA mismatch repair (MMR) family Genetic heterogeneity (MLH1, MSH2, MSH6, PMS1,
PMS2) Mutations in MMR genes lead to microsatellite instability MMR proteins are missing in the tumor tissue due to two-
hit hypothesis making immunohistochemical staining useful
![Page 48: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/48.jpg)
MSI IS CAUSED BY FAILURE OF MISMATCH REPAIR (MMR) GENES
Base pair mismatch
Normal DNA repair
Defective DNA repair (MMR+)
T CT A C
A G C T G
T C G A C
A G C T G
T CT A C
A G C T G A G A T G
T C T A C
![Page 49: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/49.jpg)
MICROSATELLITE INSTABILITY (MSI)
95% of HNPCC tumors are MSI+ 10%–15% of sporadic CRCs are MSI+ 2-3% of CRCs are due to HNPCC Therefore, ~1 in 5 MSI+ CRC is due to HNPCC Others due to acquired methylation of MLH1 promoter
![Page 50: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/50.jpg)
HEREDITARY NONPOLYPOSIS COLORECTAL CANCER (HNPCC)
MLH1
MSH2
MSH6
PMS2
![Page 51: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/51.jpg)
IMMUNOHISTOCHEMISTRY
Identify MMR proteins normally present
If protein is absent, the gene is not being expressed (mutation or methylation)
Helps direct gene testing by predicting likely involved gene
If abnormal IHC, the patient is MSI+
MSH2MLH1
PMS2MSH6
![Page 52: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/52.jpg)
GERMLINE MLH1 MUTATION
MLH1 MSH2
![Page 53: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/53.jpg)
5 POSSIBLE RESULT FROM IHC TESTING
Normal
MLH1 & PMS2
MSH2 & MSH6
MSH6 ONLY
PMS2 ONLY
![Page 54: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/54.jpg)
1. NORMAL – ALL 4 STAINS PRESENT
80% of casesCRC is probably not MSI+Prognosis worse than if MSI+Refer to Genetics if you have a patient
with polyposis, diagnosed CRC <45, has had multiple adenomatous polyps or CRC primaries.
![Page 55: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/55.jpg)
2. ABNORMAL – MLH1 & PMS2 ABSENT
15% of casesCRC is MSI+Better Prognosis 80% of these will be acquired
methylation of MLH1 and not HNPCC20% will be HNPCCRefer for genetic testing
![Page 56: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/56.jpg)
3. ABNORMAL – MSH2 & MSH6 ABSENT
3% of casesCRC is MSI+Better PrognosisMost likely HNPCC due to either
MSH2 or MSH6 gene mutationRefer for genetic testing
![Page 57: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/57.jpg)
4. ABNORMAL – MSH6 ABSENT
1% of casesCRC is MSI+Better PrognosisMost likely HNPCC due to an MSH6
gene mutationRefer for genetic testing
![Page 58: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/58.jpg)
5. ABNORMAL – PMS2 ABSENT
1% of casesCRC is MSI+Better PrognosisMost likely HNPCC due to an PMS2
gene mutationRefer for genetic testing
![Page 59: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/59.jpg)
The Family History Is Key to Diagnosing HNPCC
CRCdx 50s
CRCdx 45
CRCdx 61
CRCdx 75
OvarianCa, dx 64
CRCdx 48
CRCdx 52
EndometrialCa, dx 59
CRCdx 42
45
![Page 60: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/60.jpg)
Power of Partnership: Columbus wide study
![Page 61: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/61.jpg)
THE COLUMBUS-AREA HNPCC STUDY DESIGN
Newly dx patients with CRC or EC enrolled regardless age/family history
MSI+; IHC and mutation analysis of MLH1, MSH2, MSH6 and PMS2 genes by full sequencing of genomic DNA Methylation status MLH1 promoter evaluated by
methylation-specific PCR and bisulfite-PCR followed by restriction digestion of tumor DNA
![Page 62: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/62.jpg)
COLUMBUS HNPCC STUDY 1999-2005
MSI positiveN = 307 (19.6%)
Colorectal cancer Total accrued N = 1600
Analyzed N = 1566
MSI negativeN =1259 (80.4%)
Mutation positiveN = 44* 2.8%
Mutation result indeterminate
N = 55 3.5%
Mutation negative N =209 13.4%
Sequence MLH1, MSH2, MSH6
ImmunohistochemistryMethylation of MLH1 promoter
![Page 63: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/63.jpg)
Columbus HNPCC study
MSI positiveN = 121 22.5%
Endometrial cancerTotal accrued N = 573
Analyzed N = 538
MSI negativeN =419 77.5%
Mutation positiveN = 6* 1.1%
Mutation result indeterminate
N = 22 4.1%
Mutation negative N = 93 17.3%
Sequence MLH1, MSH2, MSH6
ImmunohistochemistryMethylation of MLH1 promoter
![Page 64: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/64.jpg)
CRC HNPCC PROBANDCHARACTERISTICS
Mean age at diagnosis – 50.4 Range, 23 to 87
39% CRC probands were not diagnosed <50 22% CRC probands did not meet
Amsterdam or Bethesda criteria 57% MSH2 mutations, 22% MLH1
mutations, 13% MSH6 mutations, 8% PMS2 mutations
![Page 65: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/65.jpg)
27 CRC & 6 ENDO probands recieved genetic counseling
Degree of Kinship Tested Positive
First 68 36
Second 30 9
> Second 44 18
Total 142 63
Columbus HNPCC study Family studies of 33 probands
![Page 66: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/66.jpg)
CONCLUSIONS
Morbidity and mortality likely reduced by identifying probands and family members at risk and counseling
In the Columbus area, the rate of MSI is 19% (CRC) and 23% (EC) and HNPCC is 2.2% (CRC) and 1.1% (EC)
Large scale screening is feasible
![Page 67: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/67.jpg)
SURVEILLANCE OPTIONS FOR CARRIERS OF HNPCC-ASSOCIATED MUTATIONS
Cancer Genetics Studies Consortium Task Force RecommendationsModified from Burke W et al. JAMA 277:915, 1997
InterventionColonoscopy
l Transvaginal ultrasound
l Endometrial aspirate
RecommendationBegin at age 20–
25, repeat every 1–2 years
Annually, starting at age 25–35
MalignancyColorectal cancer
Endometrial cancer
![Page 68: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/68.jpg)
15-year prophylactic colonoscopic screening
22 HNPCC families identified; 252 asymptomatic individuals at 50% à priori risk offered screening
133 accepted (Mean age 38.1 yrs; 73 males, 60 females)
119 declined (Mean age 38.8 yrs; 59 males, 60 females
Screening by colonoscopy every 3 years
Järvinen et al. 1995 and 2000
![Page 69: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/69.jpg)
15-year prophylactic colonoscopic screening
Screened Not screened
n=133 n=119
Colorectal cancer 8 19 n=0.014
Death from colorectal cancer 0 9 p<0.001
Overall deaths 10 26 p<0.001
Järvinen et al. 1995 and 2000
![Page 70: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/70.jpg)
SURVEILLANCE REDUCES RISK OF COLORECTAL CANCER IN HNPCC FAMILIES
Jarvinen HJ et al. Gastro 108:1405, 1995
% of subjects
with CRC
30
20
10
4.5%
11.9%
0 3 6 9Years of follow-up
Surveillance
No surveillance
0
ASCO
![Page 71: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/71.jpg)
PROPHYLACTIC SURGERY FOR HNPCC-ASSOCIATED MUTATION CARRIERS
Options include subtotal colectomy, hysterectomy, and oophorectomy
Surgery does not eliminate cancer risk
No recommendation for or against surgery has been made due to unproven efficacy
Burke et al. JAMA 277:915, 1997
![Page 72: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/72.jpg)
72
FIRST PATIENT DIAGNOSED WITH
LYNCH SYNDROME IN OCCPI
Pedigree - HNPCC
![Page 73: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/73.jpg)
73
A LEGACY OF CANCER
L to R: Uncle Jerry (colon), Grandma Ora Lee (lung), Martha (brain), Dad (colon) , Grandfather Jim Ben (colon), Aunt Reba (kidney & uterine cancer)
Father
![Page 74: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/74.jpg)
74
FIRST PATIENT DIAGNOSED WITH
LYNCH SYNDROME IN OCCPI
Pedigree - HNPCC
![Page 75: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/75.jpg)
75
CASCADE TESTING
• Family Reunion June 2014• On Mississippi River in
western Kentucky• Tested 20 at-risk relatives from
his dad’s side of the family• Found one additional branch
of family with Lynch syndrome• They can now participate in
cancer surveillance.
![Page 76: COLON CANCER GENETICS - surgerysymposium.org](https://reader035.fdocuments.in/reader035/viewer/2022080303/62e8c449533f8d66a726662a/html5/thumbnails/76.jpg)
Lynch Syndrome Key Points
All colon and rectal cancers should be screened for mismatch repair gene absence by IHC staining.
The Amsterdam and Bethesda criteria are helpful aids in identifying patients at risk, but miss up to 30% of HNPCC families.
It is desirable to identify mutation carriers, both affected and unaffected with cancer.
Close follow-up and colonoscopy reduce the cancer risk. MSI+ tumors have better prognosis than MSI-. The benefits of aggressive surgery are unproven.